Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

November 02, 2021 07:00 ET | Source: Rhythm Pharmaceuticals, Inc.

Rhythm Pharmaceuticals Reports Third Quarter 2021 Financial Results

-- U.S. and EU regulatory filings submitted for IMCIVREE® (setmelanotide) for treatment of Bardet-Biedl and Alström syndromes; launch preparations underway ---- Delivered a total of 22 presentations...
November 01, 2021 16:01 ET | Source: Rhythm Pharmaceuticals, Inc.

Rhythm Pharmaceuticals Presents First-ever Data Showing Improvements in Health-related Quality of Life for Patients Living with Bardet-Biedl Syndrome at ObesityWeek® 2021

-- Additional oral presentation details safety and efficacy data from Phase 3 trial of setmelanotide in BBS ---- Also presenting new hunger data from SRC1 and SH2B1 cohorts in Phase 2 Basket Trial and...
October 20, 2021 08:00 ET | Source: Rhythm Pharmaceuticals, Inc.

Rhythm Pharmaceuticals to Report Third Quarter 2021 Financial Results on Tuesday, November 2, 2021

BOSTON, Oct. 20, 2021 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a commercial-stage biopharmaceutical company committed to transforming the care of people living with rare...
October 15, 2021 16:11 ET | Source: Rhythm Pharmaceuticals, Inc.

Rhythm Pharmaceuticals schließt die Einreichung des Antrags für die Typ-II-Variation für IMCIVREE ® (Setmelanotid) für Bardet-Biedl- und Alström-Syndrome bei der Europäischen Arzneimittelagentur ab

BOSTON, Oct. 15, 2021 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), ein biopharmazeutisches Unternehmen im kommerziellen Stadium, das sich der Umgestaltung der Versorgung von...
October 15, 2021 16:11 ET | Source: Rhythm Pharmaceuticals, Inc.

Rhythm Pharmaceuticals completa la presentazione della domanda di variazione tipo II all'Agenzia europea per i medicinali per IMCIVREE® (setmelanotide) per le sindromi di Bardet-Biedl e Alström

BOSTON, Oct. 15, 2021 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), un'azienda biofarmaceutica in fase commerciale impegnata a cambiare radicalmente l'assistenza delle persone...
October 15, 2021 16:11 ET | Source: Rhythm Pharmaceuticals, Inc.

Rhythm Pharmaceuticals completa la presentación de la solicitud de variación de tipo II a la Agencia Europea del Medicamento para IMCIVREE® (setmelanotida) para los síndromes de Bardet-Biedl y Alström

BOSTON, Oct. 15, 2021 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), una empresa biofarmacéutica en fase comercial comprometida con la transformación de la atención a las personas...
October 15, 2021 16:11 ET | Source: Rhythm Pharmaceuticals, Inc.

Rhythm Pharmaceuticals complète la demande de variation de type II à l'Agence européenne des médicaments pour l'IMCIVREE® (setmelanotide) pour les syndromes de Bardet-Biedl et Alström

BOSTON, 15 oct. 2021 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq : RYTM), une société biopharmaceutique au stade commercial engagée à transformer les soins des personnes atteintes de...
October 14, 2021 16:01 ET | Source: Rhythm Pharmaceuticals, Inc.

Rhythm Pharmaceuticals Completes Submission of Type II Variation Application to the European Medicines Agency for IMCIVREE® (setmelanotide) for Bardet-Biedl and Alström Syndromes

BOSTON, Oct. 14, 2021 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a commercial-stage biopharmaceutical company committed to transforming the care of people living with rare...
October 14, 2021 16:01 ET | Source: Rhythm Pharmaceuticals, Inc.

Rhythm Pharmaceuticals Completes Submission of Type II Variation Application to the European Medicines Agency for IMCIVREE® (setmelanotide) for Bardet-Biedl and Alström Syndromes

BOSTON, Oct. 14, 2021 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a commercial-stage biopharmaceutical company committed to transforming the care of people living with rare...
October 14, 2021 08:00 ET | Source: Rhythm Pharmaceuticals, Inc.

Rhythm Pharmaceuticals Presents New Data on Experience of People Living with Rare Genetic Diseases of Obesity and Provides Updates on Uncovering Rare Obesity® Genetic Testing Program

-- New data in patients with POMC or LEPR deficiency obesity show setmelanotide led to clinically meaningful improvements in health related quality of life measures and hunger -- -- Updated results...